The protein deacetylase SIRT1 regulates various pathways in metabolism, aging and cancer. However, the role of SIRT1 in skin cancer remains unclear. Here, using mice with targeted deletions of SIRT1 in their epidermis in both resistant B6 and sensitive SKH1 hairless backgrounds, we show that the role of SIRT1 in skin cancer development induced by ultraviolet B (UVB) radiation is dependent on its gene dose. Keratinocyte-specific heterozygous deletion of SIRT1 promotes UVB-induced skin tumorigenesis, whereas homozygous deletion of SIRT1 suppresses skin tumor development but sensitizes the B6 mice to chronic solar injury. In mouse skin, SIRT1 is haploinsufficient for UVB-induced DNA damage repair and expression of xeroderma pigmentosum C (XPC), a protein critical for repairing UVB-induced DNA damage. As compared with normal human skin, downregulation of SIRT1 is in parallel with downregulation of XPC in human cutaneous squamous cell carcinoma at both the protein and mRNA levels. In contrast, homozygous SIRT1 deletion in mouse skin augments p53 acetylation and expression of its transcriptional target Noxa, and sensitizes the epidermis to UVB-induced apoptosis in vivo, while heterozygous SIRT1 deletion has no such effect. The gene dosagedependent function of SIRT1 in DNA repair and cell survival is consistent with the dual roles of SIRT1 in UVB-induced skin tumorigenesis. Our results reveal the gene dosage-dependent in vivo functions of SIRT1 in skin tumorigenesis and may shed light on the role of SIRT1 in epithelial cancer induced by DNA damage.
INTRODUCTION
Sirtuin 1 (SIRT1), a mammalian counterpart of the yeast silent information regulator 2 and a proto member of the sirtuin family, is an NAD-dependent protein deacetylase. It has been revealed that SIRT1 regulates important cellular processes, including metabolism, cell survival and stress response. [1] [2] [3] [4] However, the role of SIRT1 in cancer development is still under debate. [4] [5] [6] It has been considered as a tumor promoter because of its increased expression in some types of cancers and its role in inactivating proteins that are involved in tumor suppression. 6 It deacetylates and thus inhibits the tumorsuppressor p53. [7] [8] [9] SIRT1 protein levels were found to be significantly elevated in human prostate cancer, 10 acute myeloid leukemia, 11 primary colon cancer 12 and skin cancer. 13 However, SIRT1 has also been reported to mediate BRCA1 signaling and inhibit tumor growth through repressing transcription of oncogenes or activity of oncoproteins. 14, 15 By regulating the DNA repair protein Ku70, SIRT1 was shown to promote cell survival. 16, 17 Data using genetic or spontaneous tumorigenesis mouse models support a role for SIRT1 as a tumor suppressor [18] [19] [20] [21] [22] [23] and as an oncogene. 24 SIRT1 has an important role in DNA damage repair, maintains genomic integrity and suppresses spontaneous tumor development. 18 It was found to promote DNA damage repair by positively regulating NBS1. 25 Furthermore, by promoting deacetylation of xeroderma pigmentosum protein A (XPA) 26 and promoting the expression of xeroderma pigmentosum C (XPC), 27 SIRT1 promotes nucleotide excision repair, which removes ultraviolet B (UVB)-induced DNA damage. In addition, SIRT1 is downregulated in UV-associated human skin cancers, 27 suggesting that it is a tumor suppressor.
To elucidate the precise function of SIRT1 in human epithelial cancer development, we generated mice with a keratinocytespecific SIRT1 deletion and monitored tumor development following chronic UVB irradiation. We found that in mouse skin SIRT1 acts as either a tumor suppressor or an oncogene, depending on the SIRT1 gene dose, which is consistent with its role in promoting UVB-induced DNA damage repair and suppressing UVB-induced p53-mediated apoptosis. These findings may provide new insights into the mechanistic role of SIRT1 in cancer development and in cutaneous homeostasis.
RESULTS
The function of SIRT1 in UVB-induced skin carcinogenesis in B6 mice is dependent on SIRT1 gene dose To better understand the role of SIRT1 in skin tumorigenesis in which UVB is the major risk factor for humans, we first compared UVB-induced tumor formation among mice in a B6 background with normal SIRT1 (wild type (WT)), heterozygous deletion (keratinocyte-specific heterozygous SIRT1 deletion (cHet)) and homozygous deletion (keratinocyte-specific homozygous SIRT1 deletion (cKO)) specifically in their epidermis (Figures 1a-c). UVB was found to induce tumor formation in SIRT1 WT and SIRT1 cHet mice but not in SIRT1 cKO mice ( Figure 1d ). SIRT1 cHet mice started to develop skin tumors at 35 weeks of UVB radiation; however, SIRT1 WT mice did not develop tumors until 42 weeks ( Figure 1d ). A log-rank test showed that SIRT1 hemizygosity significantly accelerates skin tumorigenesis following UVB radiation (Po0.01). Histological analysis of representative tumors (Figure 1a ) showed that at the end of the study or when the mice were euthanized due to tumor burden, all the lesions were papillomas (PAPs) in WT mice and squamous cell carcinomas (SCCs) in cHet mice (Figure 1b ).
SIRT1-null deficiency predisposes B6 mouse skin to chronic UV injury
Although homozygous SIRT1 deletion prevented UVB-induced skin tumorigenesis (Figure 1 ), the cKO mice showed reduced overall survival as compared with WT and cHet mice (Figure 2a ).
When death mediated by tumor burden was excluded, the percentage of non-tumor survival in cKO mice was significantly lower than in either WT or cHet mice (Figure 2b; Po0.05; log-rank test). Following repeated UVB radiation, cKO mice developed chronic injury, which later evolved into an open lesion ( Figure 2c ). These lesions shared several common histological features with wounds, including hyperplasia in surrounding skin, and edema, ulceration and loss of epidermis in the lesion sites ( Figure 2d ), with the presence of proliferating cells that were positive for the proliferation marker Ki67 (Figure 2e ). These data demonstrate that SIRT1-null deletion sensitizes mouse skin to chronic UV injury.
Dual role of SIRT1 in UVB-induced skin tumorigenesis in SKH1 hairless mice To further determine the role of SIRT1 in skin cancer, we generated WT, cHet and cKO mice in a SKH1 hairless background, a tumor-sensitive strain that has been widely used in photocarcinogenesis. As compared with WT mice, cHet mice showed an accelerated tumor onset, increased tumor multiplicity and increased tumor growth, whereas cKO mice yielded delayed onset, decreased multiplicity and decreased tumor growth (Figures 3a-c, Supplementary Figure S2 ). Histological analysis revealed that cHet mice developed more SCCs and similar number of PAP, while cKO mice developed similar number of SCCs and fewer PAPs, as compared with WT mice (Figure 3d ). The ratio of malignant conversion from PAP to SCC was higher in both cHet and cKO mice than in WT mice ( Figure 3e ). No chronic UV injury was detected in any group. These results demonstrate that SIRT1 has a dual role in UVB-induced skin tumorigenesis depending on its gene dose and suggest that SIRT1 inhibition increases malignant conversion.
SIRT1 is haploinsufficient for UVB-induced DNA damage repair and XPC expression
In addition to regulating XPA, 26 we have recently demonstrated that in HaCaT cells and mouse embryonic fibroblasts SIRT1 promotes UVB-induced DNA damage repair through XPC, 27 which supports the tumor-suppressing role of SIRT1 in skin cancer. To determine whether SIRT1 has the same role in normal human epidermal keratinocytes (NHEK), we measured the percentage of DNA repair at different intervals post UVB in NHEK cells transfected with siRNA targeting SIRT1 or negative control siRNA (NC). Inhibition of SIRT1 reduced the expression of XPC but not XPA and inhibited repair of cyclobutane pyrimidine dimers, the major UVB-induced DNA damage product (Figures 4a and b ). To determine the function of SIRT1 in XPC expression and DNA repair in vivo, SIRT1 WT, cHet and cKO mice were irradiated with UVB (350 mJ/cm 2 ), and skin was collected at 0 and 24 h post UVB. XPC mRNA and protein levels were much lower in both cHet and cKO mouse skin than in WT skin (Figures 4c and d, Supplementary Figure S3 ). The repair of cyclobutane pyrimidine dimers was reduced in both cHet and cKO skin as compared with SIRT1 WT skin ( Figure 4e ). Addition of XPC increased the DNA repair capability in SIRT1-inhibited NHEK cells (Figures 4f and g). These results indicate that SIRT1 is haploinsufficient for XPC expression and UVB-induced DNA damage repair. To assess the specific association of SIRT1 with XPC expression, we analyzed the SIRT1 and XPC protein levels in normal human skin tissue and SCC. We found that at the protein and mRNA levels downregulation of SIRT1 is closely associated with reduced XPC expression in SCCs as compared with normal skin tissue (Figures 4h and i), further supporting the essential role of SIRT1 in maintaining XPC availability.
SIRT1-null deletion activates p53 and promotes UVB-induced apoptosis
One of the first non-histone substrates of SIRT1 identified is the tumor-suppressor p53, 7, 8, 28 leading to the proposed oncogenic role of SIRT1. SIRT1 deacetylates p53 and thus inhibits its transcriptional function to prevent apoptosis induced upon stress and DNA damage. 7, 8, 28 However, in vivo p53 deacetylation by SIRT1 in mice 29 was not confirmed in another report. 30 To quantify the effect of SIRT1 deletion on UVB-induced apoptosis in vivo, we used the TUNEL assay to measure the percentage (%) of apoptotic cells in WT, cHet and cKO mouse skin following sham or UVB radiation. SIRT1 deletion had no effect on apoptosis without UVB irradiation (Figures 5a and b ). However, following UVB irradiation, the percentage of TUNEL positive ( þ ) cells was significantly higher in cKO mouse skin than in either WT or cHet mouse skin (Figures 5a and b) , Po0.05. No significant difference was detected between WT and cHet mice.
To determine the regulation of p53 by SIRT1 upon UVB irradiation in vitro and in vivo, we analyzed the levels of acetylated p53 at K382, a known SIRT1 deacetylation site in NHEK cells and mouse skin following UVB irradiation. In NHEK cells, UVB increased p53 acetylation (Figure 5c ), consistent with previous reports in immortalized cell lines. 7, 8, 28 Inhibition of SIRT1 by transfection with siRNA targeting SIRT1 increased p53 acetylation as compared with cells transfected with NC siRNA (Figure 5c ). To determine the role of SIRT1 in p53 acetylation and apoptosis in vivo, we treated SIRT1 WT, cHet and cKO mice with UVB (350 mJ/cm 2 ) three times at intervals of every other day and collected skin tissue at 24 h following the final UVB exposure. UVB irradiation upregulated p53 levels and the expression of the pro-apoptotic p53 target genes Noxa, Puma and Bax in all the groups (Figures 5d-g) . As compared with the WT group, however, acetylated p53 was only increased in the UVB-irradiated cKO group but not in the cHet group. In shamtreated mice, acetylation of p53 was elevated in some mice, whereas UVB radiation increased p53 acetylation in all mice ( Figure 5d ). Intriguingly, SIRT1 inhibition significantly augmented Noxa induction following UVB irradiation (Figure 5e ; Po0.05; Student's t-test), while it had no effect on UVB-induced Puma or Bax upregulation (Figures 5f and g) . Knockdown of p53 reduced apoptosis in UVB-irradiated NHEK cells with SIRT1 knockdown, while it had no effect on cells transfected with negative control siRNA (siNC) (Figures 5h and i) . Similarly, overexpression of the p53K382R mutant (p53Mut) rescued apoptosis resulting from SIRT1 knockdown in UVB-irradiated NHEK cells (Figure 5i ). These data indicate that homozygous deletion of SIRT1 augmented p53 
DISCUSSION
Over the past decade, SIRT1 has attracted enormous attention due to its beneficial role in cell metabolism and survival in vitro and in vivo animal studies. [1] [2] [3] [4] However, accumulating evidence indicates that the role of SIRT1 in cancer is complex. It remains under debate whether SIRT1 acts as a tumor suppressor or as an oncogene. [4] [5] [6] In this study, using a keratinocyte-specific SIRT1 deletion and UVB-induced skin tumorigenesis model, we demonstrated that the function of SIRT1 in carcinogenesis is dependent on its gene dose. Heterozygous deletion promotes UVB tumorigenesis, whereas homozygous deletion inhibits tumorigenesis. At the molecular level in mouse skin, we found that SIRT1 is haploinsufficient for UVB-induced DNA damage repair and XPC expression. However, only homozygous SIRT1 deletion increased p53 activation and UVB-induced apoptosis in vivo, while heterozygous deletion had no such effect. Consequently, following chronic UVB radiation, mice with homozygous SIRT1 deletion developed severe solar injury, although they were protected from tumor formation, as compared with mice with WT or heterozygous SIRT1 deletion.
Intriguingly, we found that SIRT1 is haploinsufficient for UVBinduced DNA damage repair and tumorigenesis. Using HaCaT and mouse embryonic fibroblast (MEF) cells, our previous studies had shown that SIRT1 is required for efficient repair of UVB-induced DNA lesions. In a wide spectrum of UV-associated keratinocytederived neoplasms, SIRT1 expression is significantly reduced as compared with normal skin, suggesting that SIRT1 is a potential tumor suppressor in skin cancer. 31 Increasing evidence has suggested that SIRT1 has an important role in DNA repair of UV lesions and double-strand breaks. [32] [33] [34] It is noteworthy that XPC abundance is critical for efficient GG-NER (global genomic nucleotide excision repair) and thus for preventing UVB-induced skin carcinogenesis. 35, 36 Haploinsufficiency of the XPC gene is a risk factor for UVB-induced skin cancer in mice, 37 suggesting that XPC downregulation by SIRT1 inhibition has an active role in increased skin cancer susceptibility by SIRT1 deletion. In mouse skin, heterozygous SIRT1 deletion inhibited XPC expression and UVB-induced DNA repair and increased skin tumorigenesis. These results suggest that SIRT1 has an important role in maintaining genome integrity in vivo and acts as a haploinsufficient tumor suppressor in mice.
In contrast, SIRT1 is haplosufficient for cell survival in vivo following UVB damage. We found that homozygous but not heterozygous SIRT1 deletion enhances UVB-induced p53 acetylation and activation as well as apoptosis in vivo. SIRT1 has been shown to deacetylate and inactivate p53 to promote cell survival in MEF cells, fibroblasts and cell lines. 7, 8 A variety of posttranslational modifications can regulate p53 activity, including phosphorylation, acetylation, methylation and sumoylation. 38 As p53 is a well-known tumor suppressor, its inhibition by SIRT1 had categorized SIRT1 as an oncogene. However, recent studies have shown that while SIRT1 deacetylates p53, there is no biological outcome of this deacetylation. 30, 39 Our results indicate that in mouse skin SIRT1 inhibition increased p53 acetylation and expression of some p53 target genes, such as Noxa but not Puma or Bax. Deacetylation of p53 via SIRT1 may have an important role in preventing UVB-induced apoptosis in mice. XPA deacetylation by SIRT1 has been shown to play a role in UVinduced DNA repair and survival. 26 However, we were unable to detect endogenous XPA acetylation or the effect of SIRT1 deletion in either mouse skin or NHEK cells. Nevertheless, the increased apoptosis may facilitate elimination of unrepaired cells and thus reduce malignant transformation. This is consistent with the genedose-dependent role of SIRT1 in UVB-induced skin tumorigenesis.
As compared with mice with WT SIRT1, mice with heterozygous SIRT1 deletion exhibit reduced DNA repair with cell survival unaffected, supporting increased tumorigenesis, whereas mice with homozygous SIRT1 deletion exhibit both reduced DNA repair and cell survival, supporting reduced tumorigenesis as detected.
The distinct dose-dependent role of SIRT1 underscores its opposing complex functions in epithelial tumorigenesis induced by DNA damage. The role of SIRT1 in cancer is complex. Although in vivo studies have overwhelmingly supported the tumor-suppressing role of SIRT1 in genetic or spontaneous tumorigenesis mouse models, including lymphoma, sarcoma, teratoma, carcinoma of the salivary and mammary glands, 18 intestinal malignancies, 19 liver cancer 21 and prostate neoplasia, 22 SIRT1 has been demonstrated to act as an oncogene in thyroid carcinogenesis driven by PTEN deficiency. 24 In contrast, in whole-body SIRT1 knockout mice in combination with a two-stage chemical carcinogenesis model, SIRT1 was found not to affect the incidence or tumor load but was found to be required for the antitumor activity of resveratrol. 40 The discrepancy is likely due to the mixed genetic background of the mice used in this study, which can significantly affect susceptibility to tumorigenesis, and the different carcinogens used. The genetic background also determines the severity of the phenotype of SIRT1-null mice. In most cases, the loss of SIRT1 was embryonic lethal. 18 A very small proportion of SIRT1-null mice were born viable but failed to survive more than a few months beyond birth. 29, 41 Chemical carcinogenesis protocols provide a defined initiation-promotion model to study tumorigenesis in rodents over a relatively short time period. However, chronic exposure to UV light, particularly UVB, which causes DNA damage, is the major environmental risk factor in human skin carcinogenesis. Different or opposing functions of genes, including DDB2 42 and phospholipase Ce, 43 have been detected in a UV tumorigenesis model versus a chemical tumorigenesis model. Indeed, our data are consistent with recent studies in whole-body heterozygous SIRT1 deletion mice with or without p53 heterozygosity, 18 supporting a tumor-suppressing role for SIRT1 heterozygosity. Furthermore, our UVB tumorigenesis model using keratinocyte-specific SIRT1 deletion permitted us to elucidate the complex consequences of both heterozygous and homozygous SIRT1 deletion following DNA damage. Although SIRT1 homozygous deletion suppressed tumorigenesis, it increased the ratio of malignant conversion from benign PAP to SCC. These further support the multifaceted role of SIRT1 in cancer. The underlying mechanism is under investigation in our laboratory.
In summary, our results identified an essential gene dosagedependent role of SIRT1 in regulating tumorigenesis and epithelial homeostasis under genotoxic UVB stress. Heterozygous loss of SIRT1 function increases UVB tumorigenesis. Null deletion of SIRT1 suppresses tumorigenesis, while it sensitizes mouse skin to UVBinduced injury and to malignant conversion. SIRT1 is haploinsufficient for UVB-induced DNA damage repair, but haplosufficient for cell survival following UVB damage. Our results underscore the gene dosage-dependent dual roles of SIRT1 in UVB skin tumorigenesis.
MATERIALS AND METHODS

Animal treatments and UVB irradiation
All animal resources have been approved by the University of Chicago Institutional Animal Care and Use Committee. The Sirt1 allele with floxed (Jackson Laboratory, Bar Harbor, ME, USA) 44 was backcrossed into the C57BL/6 background and then bred with mice expressing Cre recombinase driven by the K14 (Jackson Laboratory) promoter to generate skin cHet and homozygous SIRT1 knockout (cKO) mice. Sirt1 flox/flox (WT) mice were used as comparison controls. Mice (n ¼ 15) were shaved 1 day before the initial UVB radiation and later as needed. Shaved mice were exposed to UVB (350 mJ/cm 2 , a dose selected to avoid visible sunburn in WT mice) dorsally or sham-irradiated, three times a week for 42 weeks and then kept for an additional 20 weeks to monitor tumor formation and growth. To generate WT, cHet and cKO mice in SKH1 hairless background, mice were backcrossed with SKH1 female for at least five times. The SKH1 mice were irradiated with UVB (100 mJ/cm 2 ) three times a week for 25 weeks as described in our recent studies. 45 Mice were housed five animals per cage, and there was no evidence of dorsal wounds caused by fighting or sunburn.
Human normal and tumor samples
All human specimens were studied after approval by the University of Chicago Institutional Review Board. Frozen tissues were obtained under consent at the Section of Dermatology, Department of Medicine, University of Chicago, Chicago, IL, USA as in our previous studies. 45 Cell culture NHEK were obtained from Clonetics (Lonza, Walkersville, MD, USA) and cultured in KGM Gold BulletKit medium (Clonetics, Lonza) according to the manufacturer's instructions. NHEK cells were cultured for less than four passages. No authentication was done.
Statistical analyses
Statistical analyses were performed using Prism 5 (GraphPad software, San Diego, CA, USA). Data were expressed as the mean of at least three independent experiments and analyzed by Student's t-test. Error bars indicate s.e.ms. Log-rank tests were used to evaluate tumor onset. A P-value of o0.05 was considered statistically significant.
The details for siRNA transfection, western blotting, real-time PCR, Determination of two major forms of UVB-induced DNA damage in genomic DNA by slot blot assay, TUNEL (terminal deoxinucleotidyl transferase-mediated dUTP-fluorescein nick end labeling) assay and sub-G1 flow cytometric analysis can be found in the Supplementary Information.
ABBREVIATIONS cHet, keratinocyte-specific heterozygous SIRT1 deletion; cKO, keratinocyte-specific homozygous SIRT1 deletion; NHEK, normal human epidermal keratinocytes; PAP, papilloma; SCC, squamous cell carcinoma; SIRT1, sirtuin 1; UVB, ultraviolet B; WT, wild-type; XP, xeroderma pigmentosum; XPC, xeroderma pigmentosum group C.
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